Two Sigma Investments LP Boosts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Two Sigma Investments LP lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 37.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,967,354 shares of the company's stock after buying an additional 540,274 shares during the quarter. Two Sigma Investments LP owned approximately 0.90% of Hims & Hers Health worth $47,571,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new position in Hims & Hers Health during the fourth quarter valued at $28,000. Raleigh Capital Management Inc. raised its position in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares during the last quarter. Blume Capital Management Inc. lifted its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new stake in Hims & Hers Health during the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.22, for a total value of $697,407.82. Following the completion of the sale, the chief financial officer now owns 113,816 shares in the company, valued at approximately $6,853,999.52. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 47,534 shares of the business's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $58.25, for a total value of $2,768,855.50. Following the completion of the sale, the chief executive officer now directly owns 285,194 shares in the company, valued at approximately $16,612,550.50. The trade was a 14.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 618,936 shares of company stock worth $25,182,692 over the last quarter. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Trading Down 3.6%

Hims & Hers Health stock opened at $62.35 on Tuesday. The company has a 50-day moving average price of $36.01 and a 200 day moving average price of $34.19. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The stock has a market cap of $13.96 billion, a P/E ratio of 141.71 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the firm earned $0.05 EPS. The business's revenue was up 110.7% compared to the same quarter last year. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Leerink Partners raised their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Bank of America raised their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $37.67.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.